Dr. Le Cong is Associate Professor of Pathology and Genetics at Stanford University, where his lab pioneers the intersection of genome engineering and artificial intelligence for biomedical discovery.
This session explores how artificial intelligence (AI) and machine learning (ML) are transforming preclinical development of gene and cell therapies. Topics include AI-driven CRISPR optimization and guide RNA design, computational AAV vector and construct engineering, ML-based safety and toxicology risk prediction, and AI-powered target identification using multi-omics data. A special focus will be given to CRISPR-GPT, an AI agent system automating gene-editing workflows, and practical guidance on how academic labs can integrate accessible AI tools into their programs. The session will also address how AI can shorten development timelines and reduce attrition before clinical translation, including a look at the evolving FDA and EMA frameworks for AI-generated preclinical evidence and what this means for your IND package.
More information to the attached flyer.
Please register HERE
